ZYME stock news · Zymeworks Inc.
Get alerts for ZYME
Follow Zymeworks Inc. (ZYME) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ZYMECitizens increased its price target for Zymeworks from $32.00 to $39.00.
Good for ZYMECitizens raised its Zymeworks share target from $32 to $39 and kept its positive rating. This favors the shares, but reports no new company results.
Zymeworks Inc. has teamed up with Roche to let them develop and sell its product ZW209.
Good for ZYMEZymeworks signed a deal giving Roche worldwide rights to develop and sell ZW209. The payment and Roche-covered costs make the news favorable, despite limits on Zymeworks' work in this area.
Zymeworks Inc. has signed an important agreement as part of a merger.
NeutralZymeworks closed a merger and took financing that adds cash and new obligations, so this filing leaves the company's prospects unchanged for now.
Theravance Biopharma, Inc. asked its shareholders to vote on important issues.
NeutralZymeworks is named as the parent in the proposed merger, but the filing does not show shareholder approval or consummation, so it does not change Zymeworks' outlook.
Theravance Biopharma, Inc. shares updates about its merger with Zymeworks and legal issues with shareholders.
NeutralZymeworks is the merger parent; one complaint names Parent and other shareholder claims could delay closing, while Theravance plans supplemental disclosures to address them.